Fine-Tuning T-cell-Targeting Therapies Through Affinity Engineering & Dosing Strategy
- Optimisation strategies for T-cell–targeting modalities: CD3 affinity modulation in T-cell engagers and dosing adaptation for T-cell co-stimulatory bispecific antibodies to improve benefit–risk, T-cell fitness and durability
- Comparative studies of two B7-H4 CD3 bispecific antibodies show that lower CD3 affinity reduces tumor cell killing and cytokine secretion while improving tolerability in cynomolgus monkeys
- Clinical acasunlimab + pembrolizumab data reveal less frequent dosing promotes T-cell rest and improves anti-tumor immune responses